Correlation analysis of serum FCAS1, Procalcitonin and SCYA25 levels with the prognosis of patients with sepsis
Serum FCAS1, Procalcitonin and SCYA25 levels in prognosis of sepsis
Abstract
Objective To explore the levels of serum Familial Cold Autoinflammatory Syndrome 1 (FCAS1), Procalcitonin, and Small Inducible Cytokine A25 (SCYA25) in patients with sepsis caused by drug-resistant Klebsiella pneumoniae (KP) infection and their relationship with prognosis.
Methods The study group consisted of 410 patients who were hospitalized to our hospital between March 2019 and March 2024 and had sepsis brought on by KP. A total of 196 drug-resistant patients with sepsis caused by KPs were classified into the drug-resistant group, and 214 nondrug-resistant patients with sepsis caused by KPs were classified into the nondrug-resistant group. According to the severity of sepsis, 410 patients with KP-induced sepsis were divided into a severe sepsis group (178 patients) and a sepsis group (232 patients). The control group consisted of an additional 410 healthy volunteers who were examined physically at our hospital throughout the same time period. It was established that drug-resistant KPs were resistant to clinical medications. The prognosis of patients with drug-resistant sepsis caused by a KP infection was split into a survival group and a death group 28 days after admission. Serum FCAS1 levels were detected via an enzyme-linked immunosorbent assay, and serum Procalcitonin and SCYA25 levels were determined via the chemiluminescence method. The diagnostic value of serum FCAS1, Procalcitonin, and SCYA25 for drug-resistant KP-induced sepsis as well as their predictive value for the mortality of patients with drug-resistant KP-induced sepsis were examined using receiver operating characteristic (ROC) curves. Multivariate logistic regression analysis was used to investigate the factors impacting death in patients with sepsis and drug-resistant KP infection.
Results A total of 250 drug-resistant KP strains were detected in 196 patients with sepsis caused by drug-resistant KPs. The resistance rates of these strains to cefazoline, ceftriaxone, ceftazidime, amtronam, imipenem and meropenem were greater than 90%. Serum FCAS1, Procalcitonin, and SCYA25 levels exhibited a statistically significant difference (P<0.05) between the severe sepsis group and the control and sepsis groups. Additionally, the sepsis group's levels were higher than those of the control group. Serum FCAS1, Procalcitonin, and SCYA25 levels were considerably higher in the drug-resistant group than in the nondrug-resistant group (P<0.05). The nonsurviving group had higher levels of serum FCAS1, Procalcitonin, SCYA25, Acute Physiology and Chronic Health Evaluation II (APACHE II), and infection-related Organ Failure Assessment (SOFA) ratings than the surviving group, while the nonsurviving group's serum ALB level was lower (P<0.05). Patients with drug-resistant KP infection and sepsis had higher serum levels of FCAS1, Procalcitonin, and SCYA25, which were risk factors for death, according to multivariate logistic regression analysis (P<0.05), whereas elevated levels of serum ALB were protective factors for death in patients with drug-resistant KP infection and sepsis (P<0.05). The results of the ROC curve analysis revealed that the areas under the curve (AUCs) of serum FCAS1, Procalcitonin, and SCYA25 and the combined diagnosis of drug-resistant KP infection sepsis were greater than those of FCAS1, Procalcitonin and SCYA25 (P<0.05), and the AUCs of the combined prediction of the three indicators for the death of patients with drug-resistant KP infection sepsis were greater than those of FCAS1, Procalcitonin and SCYA25. The AUC was calculated separately (P<0.05).
Conclusion The levels of serum FCAS1, Procalcitonin and SCYA25 in patients with drug-resistant KP-induced sepsis are relatively high. The combined detection of these three indicators has high diagnostic value for drug-resistant KP-induced sepsis and is related to the death of patients.
References
2.Li L, Xu X, Cheng P, Yu Z, Li M, Yu Z, Cheng W, Zhang W, Sun H, Song X. Klebsiella pneumoniaederived outer membrane vesicles mediated bacterial virulence, antibiotic resistance, host immune responses and clinical applications. Virulence. 2025 Dec;16(1):2449722. doi: 10.1080/21505594.2025.2449722. Epub 2025 Jan 10. PMID: 39792030; PMCID: PMC11730361.
3.Joshi PR, Adhikari S, Onah C, Carrier C, Judd A, Mack M, Baral P. Lung-innervating nociceptor sensory neurons promote pneumonic sepsis during carbapenem-resistant Klebsiella pneumoniae lung infection. Sci Adv. 2024 Sep 6;10(36):eadl6162. doi: 10.1126/sciadv.adl6162. Epub 2024 Sep 6. PMID: 39241063; PMCID: PMC11378917.
4.Ma H, Xu J, Zhang Y, Zhang R, Wu J. Relevance and antimicrobial resistance profile of Klebsiella pneumoniae in neonatal sepsis. J Matern Fetal Neonatal Med. 2024 Dec;37(1):2327828. doi: 10.1080/14767058.2024.2327828. Epub 2024 Mar 12. PMID: 38471804.
5.Song S, Yang S, Zheng R, Yin D, Cao Y, Wang Y, Qiao L, Bai R, Wang S, Yin W, Dong Y, Bai L, Yang H, Shen J, Wu C, Hu F, Wang Y. Adaptive evolution of carbapenem-resistant hypervirulent Klebsiella pneumoniae in the urinary tract of a single patient. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2400446121. doi: 10.1073/pnas.2400446121. Epub 2024 Aug 16. PMID: 39150777; PMCID: PMC11363291.
6.Gadisa E, Egyir B, Adu B, Ahmed H, Disasa G, Tessema TS. Epidemiology, antimicrobial resistance profile and management of carbapenem-resistant Klebsiella pneumoniae among mothers with suspected sepsis in Ethiopia. Ann Clin Microbiol Antimicrob. 2024 Sep 19;23(1):85. doi: 10.1186/s12941-024-00745-9. PMID: 39322956; PMCID: PMC11423506.
7.Wu W, Ni S, Zheng Y, Zhang P, Jiang Y, Li X, Yu Y, Qu T. Hypervirulent carbapenem-susceptible klebsiella pneumoniae ST412/K57 with strong biofilm formation: association with gas gangrene and sepsis. Int J Antimicrob Agents. 2024 Dec;64(6):107373. doi: 10.1016/j.ijantimicag.2024.107373. Epub 2024 Oct 30. PMID: 39486468.
8.Nonne F, Molfetta M, Belciug GF, Carducci M, Cianchi V, Zakroff C, Durante S, Zellmer C, Baker S, Stanton TD, Holt KE, Wyres K, Ravenscroft N, Gasperini G, Rossi O, Giannelli C, Berlanda Scorza F, Micoli F. The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design. Commun Biol. 2025 Jun 9;8(1):898. doi: 10.1038/s42003-025-08258-7. PMID: 40490475; PMCID: PMC12149307.
9.Fernández Vecilla D, Unzaga Barañano MJ, García de Andoin Sojo C, Díaz de Tuesta Del Arco JL. Klebsiella pneumoniae hipervirulenta ST23 como causa de neumonía cavitada y sepsis [Cavitary pneumonia and sepsis caused by ST23 hypervirulent Klebsiella pneumoniae]. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Feb;41(2):129-131. Spanish. doi: 10.1016/j.eimce.2022.11.017. PMID: 36759051.
10.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
11.Zhao D, Tang M, Ma Z, Hu P, Fu Q, Yao Z, Zhou C, Zhou T, Cao J. Synergy of bacteriophage depolymerase with host immunity rescues sepsis mice infected with hypervirulent Klebsiella pneumoniae of capsule type K2. Virulence. 2024 Dec;15(1):2415945. doi: 10.1080/21505594.2024.2415945. Epub 2024 Oct 21. PMID: 39429194; PMCID: PMC11497950.
12.Sau B, Ghosh S, Mal S, Adhikary P. Bacteriological Profile and Antimicrobial Resistance Patterns in Neonatal Sepsis: Special Reference to Klebsiella pneumoniae at a Tertiary Care Hospital in Eastern India. Cureus. 2025 Sep 6;17(9):e91735. doi: 10.7759/cureus.91735. PMID: 41058844; PMCID: PMC12500170.
13.Daoud L, Allam M, Collyns T, Ghazawi A, Saleem A, Al-Marzooq F. Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal. Eur J Clin Microbiol Infect Dis. 2023 Nov;42(11):1395-1400. doi: 10.1007/s10096-023-04671-0. Epub 2023 Oct 13. PMID: 37828413.
14.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
15.Giubelan LI, Neacșu AI, Rotaru-Zavaleanu AD, Osiac E. Antimicrobial Resistance in Sepsis Cases Due to Escherichia coli and Klebsiella pneumoniae: Pre-Pandemic Insights from a Single Center in Southwestern Romania. Healthcare (Basel). 2024 Aug 27;12(17):1713. doi: 10.3390/healthcare12171713. PMID: 39273737; PMCID: PMC11395092.
16.Kumar S, Verma A, Singh A, Naranje KM, Misra R. Colistin-resistant Klebsiella pneumoniae sepsis in neonates and infants: an alarming crisis in an Indian NICU. J Trop Pediatr. 2025 Feb 5;71(2):fmae044. doi: 10.1093/tropej/fmae044. PMID: 39953790.
17.Geleta D, Abebe G, Tilahun T, Abdissa A, Mihret A, Cataldo RJ, Workneh N, Negash AA, Beyene G. Molecular and clinical insights into extended-spectrum β-lactamase genes of Klebsiella pneumoniae isolated from neonatal sepsis in Ethiopia. BMC Infect Dis. 2024 Dec 18;24(1):1442. doi: 10.1186/s12879-024-10344-w. PMID: 39695444; PMCID: PMC11653740.
18.Gadisa E, Egyir B, Fekede E, Adu B, Danso J, Oclu A, Owusu-Nyantakyi C, Amuasi GR, Bortey A, Disasa G, Tessema TS. Epidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia. BMC Infect Dis. 2024 Dec 23;24(1):1458. doi: 10.1186/s12879-024-10366-4. PMID: 39716087; PMCID: PMC11665230.
19.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
20.Li S, Jiang J. Association of platelet dynamics for Klebsiella pneumoniae bloodstream infection patients with severe sepsis and/or septic shock. Clin Chim Acta. 2026 Jan 1;578:120530. doi: 10.1016/j.cca.2025.120530. Epub 2025 Aug 8. PMID: 40784631.
21.Zhang S, Zhang N, Han J, Sun Z, Jiang H, Huang W, Kong D, Li Q, Ren Y, Zhao S, Jiang Y, Liu P. Dynamic immune status analysis of peripheral blood mononuclear cells in patients with Klebsiella pneumoniae bloodstream infection sepsis using single-cell RNA sequencing. Front Immunol. 2024 Jun 5;15:1380211. doi: 10.3389/fimmu.2024.1380211. PMID: 38898888; PMCID: PMC11185935.
22.Liu R, Xu H, Zhao J, Hu X, Wu L, Qiao J, Ge H, Guo X, Gou J, Zheng B. Emergence of mcr-8.2-harboring hypervirulent ST412 Klebsiella pneumoniae strain from pediatric sepsis: A comparative genomic survey. Virulence. 2023 Dec;14(1):233-245. doi: 10.1080/21505594.2022.2158980. PMID: 36529894; PMCID: PMC9794005.
23.Mizusawa Y, Sawada H, Idani H, Nakano K, Yoshimitsu M, Shimizu A, Une Y, Mashima H, Yoshimoto M, Katsura Y, Ishida M, Satoh D, Yoshida R, Choda Y, Shirakawa Y, Matsukawa H, Shiozaki S. A 72-Year-Old Diabetic Man with Carcinoma of the Ileocecal Region, Sepsis Due to Klebsiella pneumoniae, and Hepatic Portal Venous Gas. Am J Case Rep. 2024 Sep 29;25:e944094. doi: 10.12659/AJCR.944094. PMID: 39342423; PMCID: PMC11446257.
24.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
25.Wu R, Cui X, Pan R, Li N, Zhang Y, Shu J, Liu Y. Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2025 Apr;44(4):779-788. doi: 10.1007/s10096-025-05048-1. Epub 2025 Jan 24. PMID: 39853642.
26.Teshome BF, Park T, Arackal J, Hampton N, Kollef MH, Micek ST. Preventing New gram-negative Resistance Through Beta-lactam De-escalation in Hospitalized Patients With Sepsis: A Retrospective Cohort Study. Clin Infect Dis. 2024 Oct 15;79(4):826-833. doi: 10.1093/cid/ciae253. PMID: 38842541.
27.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
28.Soni P, Matoria R, Nagalli MM. Antibiotic strategies for neonatal sepsis: navigating efficacy and emerging resistance patterns. Eur J Pediatr. 2025 Jun 24;184(7):439. doi: 10.1007/s00431-025-06271-w. PMID: 40555905.
29.Gadisa E, Egyir B, Adu B, Ahmed H, Disasa G, Tessema TS. Epidemiology, antimicrobial resistance profile and management of carbapenem-resistant Klebsiella pneumoniae among mothers with suspected sepsis in Ethiopia. Ann Clin Microbiol Antimicrob. 2024 Sep 19;23(1):85. doi: 10.1186/s12941-024-00745-9. PMID: 39322956; PMCID: PMC11423506.
30.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
31.Wake RM, Govender NP. mGem: Sepsis and antimicrobial resistance in the context of advanced HIV disease. mBio. 2025 May 14;16(5):e0076924. doi: 10.1128/mbio.00769-24. Epub 2025 Apr 11. PMID: 40214248; PMCID: PMC12077103.
32.Virk HS, Biemond JJ, Earny VA, Chowdhury S, Frölke RI, Khanna SM, Shanbhag V, Rao S, Acharya RV, Balakrishnan JM, Eshwara VK, Varma MD, van der Poll T, Wiersinga WJ, Mukhopadhyay C. Unraveling Sepsis Epidemiology in a Low- and Middle-Income Intensive Care Setting Reveals the Alarming Burden of Tropical Infections and Antimicrobial Resistance: A Prospective Observational Study (MARS-India). Clin Infect Dis. 2025 Feb 5;80(1):101-107. doi: 10.1093/cid/ciae486. PMID: 39352692; PMCID: PMC11797389.
33.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
34.Maghembe RS, Magulye MAK, Eilu E, Sekyanzi S, Makaranga A, Mwesigwa S, Katagirya E. A sophisticated virulence repertoire and colistin resistance of Citrobacter freundii ST150 from a patient with sepsis admitted to ICU in a tertiary care hospital in Uganda, East Africa: Insight from genomic and molecular docking analyses. Infect Genet Evol. 2024 Jun;120:105591. doi: 10.1016/j.meegid.2024.105591. Epub 2024 Apr 10. PMID: 38604286; PMCID: PMC11069293.
35.Mei M, You Y, Tan N, He X, Huang J. EZH1 deficiency promotes ferroptosis resistance by activating NRF2 in sepsis-associated liver injury. Clin Epigenetics. 2025 Jun 9;17(1):96. doi: 10.1186/s13148-025-01892-2. PMID: 40490833; PMCID: PMC12147250.
36.Manika MM, Tano AK, Kapend'a LK, Mujing'a FM, Kakisingi CN, Matanda SK, Wa Mwanza Teta I, Mukalay YB, Kasamba EI, Barhayiga BN, Mwamba CM, Tambwe A Nkoy Mwembo A, Nani-Tuma Situakibanza H, Iteke RF. Bacteriological profile and antimicrobial resistance in sepsis cases in intensive care units in Lubumbashi: challenges and perspectives. Ann Clin Microbiol Antimicrob. 2025 Jul 16;24(1):42. doi: 10.1186/s12941-025-00811-w. PMID: 40671057; PMCID: PMC12265319.
Copyright (c) 2026 Yanhong Yang, Yali Hua, Jing Yuan, Qingmei Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.